US Stocks prediction

In an unexpected plot twist, Ellis Investment Partners decided to expand their GPIX holdings by 64,462 shares during Q3. The value of this little corporate shopping spree? $3.3 million. So, yeah, not exactly pocket change. As of September 30, Ellis held a total of 107,147 shares, worth about $5.6 million. If you’re thinking this sounds like the stock market equivalent of “treat yo’ self,” you’d be correct. But this is about dividends, not brunches with avocado toast. Stay with me.

Per their SEC filing, these healthcare heroes bought 462,368 shares of IXUS during Q3. Let’s parse that: A group whose job is to keep people alive is now betting a chunk of change on a fund that tracks 4,000+ companies from Tokyo to São Paulo. Because nothing says “holistic care” like betting $38 million on a spreadsheet. [Winks at the irony.]

The SEC’s parchment revealed that Adventist Health System West, a nonprofit entity with a penchant for balancing portfolios and souls, offloaded its entire holding in EMXC during Q3. The fund shed 837,660 shares, a sum that would buy a small island in the Pacific, if only the banks allowed it. The estimated value? A tidy $52.9 million, enough to fund a modest quest for the Holy Grail of diversification.

According to a filing with the Securities and Exchange Commission released Tuesday, Apricus Wealth acquired 42,386 shares of ONEOK during the third quarter. The estimated transaction value, based on the average closing price for the quarter, was approximately $3.3 million. Apricus Wealth reported holding a total of 45,086 shares of ONEOK at the end of the quarter.

On October 15, 2025, under skies heavy with the weight of spreadsheets and stock tickers, Kullman exercised her vested rights to Class C Common Stock. These are not the fruits of labor in the old sense-no calluses earned here-but the quiet rewards of boardroom vigilance. The sale followed three prior administrative filings, each a breadcrumb in the trail of corporate stewardship.

In a move that could either signal a midlife crisis or a masterclass in portfolio yoga, Montreal’s Jarislowsky Fraser trimmed its Thomson Reuters (TRI 0.17%) position by 124,059 shares during Q3. The SEC got its fix via Form 13-F, and math wizards calculated the sale at roughly $22.8 million using that magic number: the average share price. For context, the fund still holds 2.9 million shares worth $448.3 million-enough to buy a small island and name it after their CFO.

Post-purchase, RDVY’s weight in the portfolio sits at 4.7%, trailing behind QQQ (7.3%), VOO (6.9%), and AAPL (5.9%). The ETF’s price, $67.00, has risen 11.9% year-over-year-impressive, if you ignore the S&P 500’s 15.18% surge. And yes, the dividend yield of 1.30% feels like a whisper in a world of shouting. But remember, history favors the patient. Or, as one monk once said: “Dividends are the slow drip that carves canyons.” 🏞️

THE SEC FILINGS CAME IN LIKE A BULLET TO THE HEAD. JARISLOWSKY FRASER LTD. SLIPPED INTO RB GLOBAL DURING THE THIRD QUARTER, A 1.8-MILLION-SHARE STAKE THAT SOUNDS LIKE A BURGER MEAL FOR A HUNGRY FUND. THE AVERAGE PRICE? $100.58. THE FUND HADN’T OWNED A SINGLE SHARE LAST QUARTER. IT’S LIKE THEY WERE WAITING FOR THE RIGHT MOMENT TO PULL THE TRIGGER.

The filing, a parchment etched with the ink of quarterly averages, reveals a pattern: Cadinha’s stake in General Electric (GE +2.09%) swells to 97,280 shares, valued at $29.3 million. To the uninitiated, this is a ledger entry. To the connoisseur of markets, it is a reflection in a mirror that reflects no end. For what is a stock price if not the sum of all expectations, a recursive echo of supply and desire?

In the third quarter, the entity reduced its position by approximately 221,600 shares, a gesture toward equilibrium in the face of an ascending stock price. The valuation, derived from an average closure, amounted to $30 million. Post-transaction, the fund retained 4.9 million shares, their cumulative worth hovering at $722.4 million-a figure that, in the grand design of the system, seemed neither excessive nor insufficient.